The Quiet Round
Prenuvo closed a $120 million Series B in 2024 and didn't announce it until February 2025, after the company had already generated $100 million in revenue, operated profitably across 17 owned clinics in North America, and scanned more than 110,000 members. The round, co-led by Forerunner Ventures, Left Lane Capital, and existing investor Felicis Ventures, brings total known funding to at least $190 million across two large rounds in roughly 14 months.
Felicis led the $70 million Series A in late 2022. The new syndicate reflects where consumer health meets institutional capital. Forerunner brings a thesis around "longevity as the new luxury," partner Brian O'Malley said in February 2025. Left Lane Capital adds a consumer-scaling playbook. The cap table also includes Cindy Crawford, Eric Schmidt, Anne Wojcicki, and Tony Fadell, names that appeared in the 2023 CNBC profile. Their participation predates the Series B; whether they followed on in 2024 isn't publicly confirmed.
What distinguishes this round isn't just the size — it's the timing relative to revenue. A profitable, $100M-revenue company raising $120M at a growth-stage valuation is unusual in healthtech, where cash burn typically precedes scale. The disconnect signals the capital isn't for survival. It's for speed: new modalities (blood biomarkers, brain health scans), international clinics (Europe, Australia), and the AI infrastructure to turn 170,000-plus member scans into a proprietary training set, an asset competitors can't replicate.
The round also arrived as the preventive imaging category attracts regulatory scrutiny. The American College of Radiology issued a formal statement in April 2023: "To date, there is no documented evidence that total body screening is cost-efficient or effective in prolonging life." The U.S. Preventive Services Task Force, which drives insurance coverage decisions under the Affordable Care Act, has not endorsed whole-body MRI for any asymptomatic population. Prenuvo's response — raising quietly, then announcing alongside FDA-cleared AI products and a 15-clinic expansion plan, frames capital as a moat-building tool rather than a runway extender.
The question the quiet close raises: what does a profitable scanning company need $120 million for? The answer unfolds in the product roadmap, the hiring plan, and the partnership structure, each funded by this round, each designed to move Prenuvo from a scan provider to a health intelligence platform.
AI Roadmap: From Screening to Longitudinal Intelligence
The Series B closed with a regulatory milestone already in hand. Prenuvo secured FDA 510(k) clearance for its AI-powered Body Composition report in early 2025, disclosed alongside the funding announcement and the 110,000-member threshold. The clearance covers software that quantifies visceral fat, liver fat, muscle volume, and key organ measurements from the same whole-body MRI sequences used for disease screening, requiring no additional scan time and no contrast agent. That report now ships with every Prenuvo scan, turning a screening tool into a metabolic health baseline.
The body-composition module is the first FDA-cleared AI product in Prenuvo's pipeline, but the research digest shows broader algorithmic ambition. An investigational aneurysm-detection model, demonstrated on the company's website, automatically highlights and measures arterial bulges in the brain when scan data reaches the radiologist workstation. The same framework extends to the new Advanced Brain Health Scan, which adds quantitative neuroimaging biomarkers to the standard protocol. The brain-health add-on has been described as a "cognitive baseline" that enables longitudinal tracking of neurodegenerative risk, not just snapshot detection.
Those algorithms don't train themselves. Prenuvo's research partnerships — Mount Sinai, UCLA Health, Johns Hopkins, Sutter Health, Penn, Brown, Baptist Health, Stanford, supply the annotated imaging datasets and clinical endpoints needed to move models from investigational to cleared. The company's prospective study established initial performance benchmarks: multiple organs and body systems assessed in under 60 minutes with AI-assisted triage. That dataset, now growing past 170,000 patients, is the compounding asset the Series B is designed to protect and expand.
Hiring data from Zero G Talent's board confirms the capital is flowing into AI headcount. A Senior AI Applied Scientist II role in Vancouver lists a $150,000–$177,000 band, while two Staff Engineer, User Experience (Backend), positions in Toronto and Vancouver sit at $180,000–$210,000. Both roles are hybrid, anchored to the Canadian R&D hubs that have housed the company's engineering core since its 2018 Vancouver founding.
The real value of proactive imaging is not in any one scan; it is in the longitudinal dataset that accumulates over time.
That line, published on Prenuvo's own site, frames the AI roadmap as a data-compounding strategy. A lesion stable across three annual scans carries different clinical weight than a lesion seen once; a biomarker drifting 15 percent over two years triggers intervention where a single blood panel would not. The Body Composition report is the first productized output of that philosophy: visceral fat and liver fat trajectories, tracked year over year, become metabolic early-warning signals rather than static snapshots. Dr. Durand, Prenuvo's chief medical officer, told Prevention.com in July 2025 that the company was "working every day to harness the powers of artificial intelligence to become more efficient, which would allow them to bring prices down long-term." Efficiency here means two things: reducing the radiologist read time per scan through AI pre-screening, and amortizing the fixed cost of model development across a growing member base.
The competitive implication is clear. Rivals such as Ezra have added whole-body MRI services, but neither has paired a cleared AI body-composition product with a longitudinal membership model backed by academic research partnerships. Neko Health raised substantial capital in 2024 for its own AI-driven body scanning platform, yet its U.S. rollout remains in waitlist phase. Prenuvo's FDA clearance, live product, and 170,000-patient dataset represent a first-mover advantage that the Series B is structured to widen, provided the algorithms keep clearing regulatory hurdles and the hiring pipeline delivers the engineering throughput to ship them.
Clinic Footprint: Bricks, Mortar, and the Next 12 Months
Prenuvo's Las Vegas clinic opened at 350 S. Rampart Blvd. in Tivoli Village on a Monday in early May 2025, the company's first Nevada outpost and the clearest signal yet that the Series B is funding bricks-and-mortar growth, not just R&D. The location runs Monday through Friday, 8 a.m. to 4 p.m., and offers three scan tiers: whole-body for $2,499, head-and-torso for $1,799, and torso-only for $999. Dr. Daniel James Durand told the Las Vegas Review-Journal the company "knew that this would be a successful location before we opened"; the West Coast, he said, attracts people "a little more proactive about their health. They're innovative, they're open to new things."
That clinic brings Prenuvo's total to 19 operating sites across the United States and Canada, with a 20th already in the pipeline. The network spans major metros — Redwood City, Chicago at 1035 W Van Buren St., and now Las Vegas, each staffed by radiologists, MRI technologists, preventive-health physicians, and nurse practitioners. The company claims more than 170,000 patients scanned to date.
Toronto is the next strategic node, but not as a scanning site, at least not yet. Prenuvo has planted a sales headquarters at 5200 Yonge Street, hiring inside sales representatives for a hybrid, full-cycle role the job posting describes as "heavy emphasis on consultative selling" with "little-to-no prospecting leads" because marketing generates inbound flow. The same board data shows a Clinic Manager role posted for Atlanta at $120,000–$150,000, signaling that the 20th clinic may land in Georgia.
| Market | Status | Role Posted | Salary Band |
|---|---|---|---|
| Las Vegas | Open (May 2025) | — | — |
| Toronto | Sales HQ active | Inside Sales Rep | Not disclosed |
| Atlanta | Clinic Manager hired | Clinic Manager | $120k–$150k |
The waitlist page on Prenuvo's site collects email addresses for "upcoming locations", a low-cost demand signal that doubles as a launch queue. Meanwhile, the scan protocol itself hasn't changed: 45 to 75 minutes depending on tier, no contrast, no radiation, results delivered through the app with a virtual radiologist consult. The Las Vegas opening proves the playbook: pick a wealthy, health-forward suburb, staff it with a luxury feel, and let the celebrity halo (Kim Kardashian, Maria Menounos) do the top-of-funnel work. Atlanta will test whether the model translates to the Southeast. Toronto will test whether a sales-first beachhead can convert a single-payer-adjacent market where preventive MRI still sits outside provincial coverage. The next 12 months answer both.
Sales Force: Building the Lever
Prenuvo's Series B is translating directly into a measurable sales hiring push. Zero G Talent's board shows the company added roles in the past seven days: an Account Manager, Physician Relations covering Northern California (San Francisco/San Jose) at $150,000–$200,000, and an Inbound Sales Representative based in Toronto. The board's salary band across 24 salaried roles runs $48,000–$197,000 with a $110,000 median.
Public postings confirm the geographic spread. A LinkedIn listing for an Inside Sales Representative at the Toronto Sales Headquarters (5200 Yonge Street) describes a hybrid, full-cycle role heavy on consultative selling, with the same inbound-flow model. The physician-relations role demands credibility with clinical stakeholders, a different muscle than direct-to-consumer closing.
The profile Prenuvo is building for is consistent across postings: candidates who can handle a high-ticket, membership-based sale (Core scans start at $1,199; Executive tiers reach $5,899) to both consumers and B2B partners. The Toronto inside-sales role emphasizes consultative skills over cold outreach.
The hiring velocity matches the capital deployment. With 170,000-plus patients scanned and a 200-plus clinical team (radiologists, technologists, preventive-health physicians, nurse practitioners), the sales organization is the lever that converts clinic capacity into recurring membership revenue. The $120M round buys the runway to scale that lever across new markets before insurers broadly reimburse.
Partnerships: Building a Private Reimbursement Layer
Prenuvo's go-to-market strategy has always leaned on employers and membership organizations to bridge the gap between a $2,500 scan and the consumer willing to pay for it. The fresh capital accelerates that playbook.
The first insurer partnership landed in June 2024. John Hancock, through its Vitality wellness program, began offering members a $500 discount on Prenuvo's whole-body MRI. The arrangement is not coverage — Vitality members still pay the balance out of pocket, but it marks the first time a major life insurer has attached its brand to preventive whole-body imaging. Fortune reported the deal as a press-release announcement, and Prenuvo's leadership framed it as a proof point for the broader thesis: that early detection reduces downstream claims. Andrew Lacy has said he hopes insurance providers will eventually agree to cover the scans outright. For now, the industry has not moved. Verywell Health noted in July 2026 that no insurance companies cover the service through companies like Prenuvo.
The Warriors Program extends the same logic to first responders, military members, and veterans. Discounted services for those groups serve both mission and marketing. Prenuvo's leadership has described the long-term vision in dental terms. Ferreira, a company executive, told Fortune the goal is to make a Prenuvo scan as routine as a teeth cleaning or an annual physical, something you schedule every six months to two years depending on risk tolerance. At $2,500 per visit, that cadence only works if someone else subsidizes it.
The numbers underneath the vision are stark. The Health Care Cost Institute puts preventive care at just 3.5 percent of total U.S. health spending. Lacy argues that shifting that ratio — even modestly, would make the system leaner by catching cancer, aneurysms, and metabolic disease before they become expensive emergencies. So Prenuvo builds its own reimbursement layer, one employer and one affinity group at a time. The company's sales team, now expanding in Toronto and across the U.S., carries that pitch deck into benefits renewal cycles.
Competition and Regulation: The Cash-Pay Ceiling
Prenuvo's Series B has not gone unnoticed. The preventive imaging market is tightening, and the company's best-funded rivals are moving on multiple fronts, some by copying the clinic model, others by doubling down on adjacent technologies, and all of them under a regulatory cloud that has yet to lift.
Ezra, the New York–based competitor that has offered full-body MRI since 2018, is expanding its own footprint but with a different labor strategy. Zero G Talent's board data shows Ezra added just one role in the past week — a Country Finance Director in Botswana at $10–15 per hour, while Prenuvo posted six roles in the same window, including that Vancouver AI role at $150,000–$177,000 and the Atlanta clinic-manager role at the same $120,000–$150,000 band. The contrast is stark: Ezra's recent hiring skews toward back-office finance in emerging markets, whereas Prenuvo is staffing clinical operations and AI development in North America. Ezra's salary band on the board runs $21,000–$31,000 (median $31,000) across a single salaried role; Prenuvo's spans $48,000–$197,000 (median $110,000) across 24 roles. That gap reflects two different bets, Ezra on lean international scaling, Prenuvo on high-cost clinical density.
SimonMed Imaging, Rayus Radiology, and Longhorn Imaging have all added whole-body MRI services in recent years. These are not startups; they are established radiology groups with existing scanner fleets, insurance contracts, and referring-physician networks. They can bolt a preventive protocol onto a 3T magnet they already own and bill the technical component to payers when a diagnostic indication exists. Prenuvo, by contrast, operates cash-pay only; its scans are not covered by insurance. That gives the incumbents a structural advantage: they can offer a "screening" add-on during a medically necessary exam, capturing the same patient without the $2,500 out-of-pocket barrier.
The clinical literature reinforces skepticism. A 2019 meta-analysis of 12 studies covering more than 5,000 asymptomatic individuals, published in the Journal of Magnetic Resonance Imaging, found incidental and indeterminate findings were common across six studies, with a 16% false-positive prevalence. Radiologists who reviewed Prenuvo scans for Fortune and Prevention described the same pattern: moderate and minor findings that trigger cascade testing — biopsies, follow-up MRIs, specialist visits, without clear mortality benefit. Dr. Matthew Davenport, a body imaging specialist at the University of Michigan, cited South Korea's 1999 thyroid ultrasound screening program: incidence rose six-fold over a decade, almost entirely from overdiagnosis of small, indolent tumors, while thyroid-cancer mortality barely moved. "The same thing can happen when companies offer broad screenings to healthy patients," he told Verywell Health.
Prenuvo's leadership acknowledges the evidence gap. CEO Andrew Lacy has said the company needs long-term outcome data before insurers will cover the scan. He frames the service as additive — "layer on top of existing screenings", not a replacement for mammography, colonoscopy, or low-dose CT lung screening. But the disclaimer at the top of every Prenuvo report, listing the standard screenings the MRI does not replace, underscores the regulatory reality: the service sits outside guideline-based care, and the burden of proof remains on the company.
For now, the competitive response is bifurcated. Incumbents like SimonMed are absorbing the protocol into existing workflows. The FDA, ACR, and USPSTF have drawn a line: show us the mortality data, or stay in the cash-pay lane. Prenuvo's $120 million buys clinic build-out, sales headcount, and AI refinement — but it does not buy guideline adoption. That requires a prospective trial with hard endpoints, and no one in the category has started one. The quiet round bought everything except the one thing that would make the model inevitable: proof that the scans save lives. Until that trial exists, the company is building a very expensive waiting room.
[U.S. investors, Big Pharma race to find new medicines in China](https://www.cnbc.com/2025/02/13/china-biopharma-deals-rise-with-summit-merck.html? __source=OTS%7Cfinance%7Cinline%7Cstory%7C&par=OTS&doc=108102031)
[CVS CEO defends pharmacy middlemen, accuses drugmakers of 'monopolistic' practices](https://www.cnbc.com/2025/02/12/cvs-ceo-defends-pbms-accuses-drugmakers-of-monopolistic-practices.html?
[Apple launches first major health study in 5 years. Here's how you can opt in](https://www.cnbc.com/2025/02/12/apple-launches-apple-health-study-with-brigham-and-womens-hospital.html?
The day in December that CNBC reported Merck announced it was licensing an experimental obesity pill from China's Hansoh for up to $2 billion, shares of U.S. company Viking Therapeutics plunged 18%. Viking is seen as an acquisition target since it's developing drugs in the red-hot obesity space, and suddenly it looked like one possible suitor had chosen to spend its money elsewhere.
People see parallels to what happened in the artificial intelligence space when China's DeepSeek declared it had created a model that was just as good as U.S. models for much less than American companies are spending.
President Donald Trump or U.S. policymakers could see the similar trend in biotech as a threat and intervene to stop these deals, what Yu calls the "stroke of a pen" risk. Lawmakers last year floated the Biosecure Act that would have restricted U.S. companies from working with Chinese contract manufacturers.
Washington has already embraced protectionist policies in other competitive areas like artificial intelligence and semiconductors. It's possible that could extend to life sciences.
"The deeper message from DeepSeek is that we have competition in the high sciences in general, and moreover that China is making major investments to develop scientific assets," said Stifel's Opler.
Put another way: the race in biopharma is on.
Working in frontier tech? Zero G Talent tracks the openings: see every open Prenuvo role, browse frontier tech jobs, openings at Ezra, and the people building the field.